Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.78 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118537 | 0.89 | EPHX1 (0.97) | EPHX1EPHX2CA12CA1CA2 | |
| SCHEMBL4012534 | 0.89 | EPHX1 (0.91) | EPHX1EPHX2CA12CA1CA2 | |
| SCHEMBL4122629 | 0.88 | EPHX1 (1.00) | EPHX1EPHX2CA12CA1CA2 | |
| SCHEMBL4016714 | 0.88 | EPHX1 (1.00) | EPHX1EPHX2CA12CA1CA2 | |
| SCHEMBL5142050 | 0.88 | EPHX1 (1.00) | EPHX1EPHX2CA12CA1CA2 | |
| SCHEMBL19708436 | 0.86 | EPHX1 (0.76) | EPHX1EPHX2CA12CA1CA2 | |
| SCHEMBL2014950 | 0.86 | EPHX1 (0.70) | EPHX1EPHX2CA12CA1CA2 | |
| SCHEMBL28590226 | 0.85 | EPHX1 (0.74) | EPHX1EPHX2CA12CA1CA2 | |
| SCHEMBL89460 | 0.83 | EPHX2 (0.56) | EPHX1EPHX2CA1CA2 | |
| SCHEMBL18926997 | 0.83 | EPHX1 (0.70) | EPHX1EPHX2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | claimed |
| WO-2008112022-A1 | 4 -PI PERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227780-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885CA12 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.